Printer Friendly

SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION BEGIN DISTRIBUTION OF PROXY STATEMENT TO STOCKHOLDERS

 SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION BEGIN DISTRIBUTION
 OF PROXY STATEMENT TO STOCKHOLDERS
 MOUNTAIN VIEW, Calif., July 28 /PRNewswire/ -- Scios Inc. (NASDAQ: SCIO) and Nova Pharmaceutical Corporation (NASDAQ: NOVX), Baltimore, MD., announced today that the United States Securities and Exchange Commission (SEC) has declared effective the S-4 registration statement filed in conjunction with the joint proxy statement for the proposed merger of Scios and Nova. On May 13, Scios and Nova announced an agreement to merge in which holders of Nova common stock will exchange each of their Nova shares for 0.39 shares of Scios.
 On July 29, 1992, the two companies will begin distributing the proxy statements to stockholders of record at July 10, 1992. Special meetings of stockholders to vote on the proposed merger will be held by each company on Sept. 3, 1992, at 11 a.m. local time.
 The information agent and proxy solicitor for both Scios and Nova is D.F. King & Co., Inc., 77 Water St., New York, N.Y. Contact: Thomas Long 212-493-6920.
 Nova Pharmaceutical Corporation based in Baltimore, MD., is engaged in the discovery, development and commercialization of pharmaceutical products which address areas of significant medical need. The company's research and development programs are in three principle areas: inflammmation, central nervous disorders, and drug delivery systems. The company's scientific strategy is to employ the tools of receptor technology, rational drug design, and drug delivery technologies to develop novel therapeutic products.
 Scios, Inc. (formerly California Biotechnology Inc.) is a biopharmaceutical company engaged in the discovery , development and commercialization of novel human therapeutics. Scios focuses its efforts in three areas: cardiopulmonary disease, tissue repair, and metabolic disorders. The company develops and commercializes products on a proprietary basis and in collaboration with established pharmaceutical companies.
 -0- 7/28/92
 /CONTACT: Virginia Walker of Scios, 415-940-6634 or 415-940-6631; Kira Bacon 410-558-9465 or Michael Demchuk 410-558-9569, both of Nova or Lynne Brum of Feinstein Partners, 617-577-8110 for Scios/
 (SCIO NOVX) CO: Scios, Inc., Nova Pharmaceuticals Corporation ST: California, Maryland IN: MTC SU:


TM -- NE015 -- 4217 07/28/92 15:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 28, 1992
Words:345
Previous Article:ANADARKO DECLARES DIVIDEND
Next Article:LTV REPORTS $138.6 MILLION SECOND QUARTER INCOME
Topics:


Related Articles
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION AGREE TO MERGE
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION MERGER CLEARS FTC REVIEW
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION RECEIVE STOCKHOLDER APPROVALS TO MERGE THE TWO COMPANIES
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION COMPLETE MERGER TO FORM SCIOS NOVA INC.
SCIOS NOVA EXERCISES OPTION TO PURCHASE INTERESTS IN NOVA TECHNOLOGY LIMITED PARTNERSHIP
SCIOS NOVA INC. ANNOUNCES SALE OF NOVASCREEN BUSINESS
SCIOS NOVA ANNOUNCES 1993 SECOND QUARTER AND SIX-MONTH FINANCIAL RESULTS
Scios Board to Oppose Proxy Contest by Randal J. Kirk.
Scios Board Mails Letter and Proxy Statement to Stockholders For February 28, 2000 Annual Meeting.
Scios and R. J. Kirk Agree to End Proxy Contest.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters